Unique ID issued by UMIN | UMIN000051278 |
---|---|
Receipt number | R000058486 |
Scientific Title | Glucagon-like peptide-1 receptor agonists decrease cancer incidences in type 2 diabetes: A cohort study using the database of Health Insurance Claims and Specific Health Checkups of Gifu and Mie Prefecture in Japan |
Date of disclosure of the study information | 2023/06/07 |
Last modified on | 2023/06/07 13:30:47 |
Glucagon-like peptide-1 receptor agonists decrease cancer incidences in type 2 diabetes: A cohort study using the database of Health Insurance Claims and Specific Health Checkups of Gifu and Mie Prefecture in Japan
Glucagon-like peptide-1 receptor agonists decrease cancer incidences in type 2 diabetes: A cohort study using the database of Health Insurance Claims and Specific Health Checkups of Gifu and Mie Prefecture in Japan
Glucagon-like peptide-1 receptor agonists decrease cancer incidences in type 2 diabetes: A cohort study using the database of Health Insurance Claims and Specific Health Checkups of Gifu and Mie Prefecture in Japan
Glucagon-like peptide-1 receptor agonists decrease cancer incidences in type 2 diabetes: A cohort study using the database of Health Insurance Claims and Specific Health Checkups of Gifu and Mie Prefecture in Japan
Japan |
Type2 diabetes
Endocrinology and Metabolism |
Malignancy
NO
In Japanese patients with diabetes mellitus (DM), the risk in total cancer incidence had been increased up to 20%, and nowadays, the leading cause of death in Japanese patients with DM is cancer, that amounted to 38% and had been in increased trend with aging. The real-world evidence of cancer incidences in users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited for Asian. The aim of this study is to clarify the cancer incidences in GLP-1 RA users compared to non-users (controls) using the Japanese data from the database of Health Insurance Claims and Specific Health Checkups of Gifu Prefecture and Mie Prefecture.
Safety
All cancer incidences during observation period
All cardiovascular events during observation period
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Type2 Diabetes
the patients under 20 years old, treated without anti-diabetic drugs, not treated new drugs during observation period, with cancer, or undergoing dialysis treatment.
50000
1st name | Ryoichi |
Middle name | |
Last name | Ishibashi |
Kimitsu Chuo Hospital
Medicine, division of Diabetes, Endocrinology and Metabolism
2920822
1010 Sakurai, Kisarazu, Chiba
0438361071
ishibashi-cib@umin.net
1st name | Ryoichi |
Middle name | |
Last name | Ishibashi |
Kimitsu Chuo Hospital
Medicine, division of Diabetes, Endocrinology and Metabolism
2920822
1010 Sakurai, Kisarazu, Chiba
0438361071
ishibashi-cib@umin.net
Kimitsu Chuo Hospital
None
Other
Kimitsu Chuo Hospital
1010 Sakurai, Kisarazu, Chiba
0438361071
soumu@kc-hosp.or.jp
NO
2023 | Year | 06 | Month | 07 | Day |
Partially published
356266
No longer recruiting
2019 | Year | 11 | Month | 18 | Day |
2020 | Year | 03 | Month | 31 | Day |
2019 | Year | 11 | Month | 18 | Day |
2024 | Year | 03 | Month | 31 | Day |
Currently analyzing
2023 | Year | 06 | Month | 07 | Day |
2023 | Year | 06 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058486